These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2015. Final rule. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2014 Mar; 79(47):13743-843. PubMed ID: 24693562 [TBL] [Abstract][Full Text] [Related]
6. A high-value network for Medicare. Davis K Hosp Health Netw; 2013 Jul; 87(7):12. PubMed ID: 23961580 [No Abstract] [Full Text] [Related]
7. Coordination of benefits. Anderson LS Issue Brief Cent Medicare Educ; 2003; 4(10):1-6. PubMed ID: 14992217 [TBL] [Abstract][Full Text] [Related]
8. Payer management of oncology gets serious. Snyder M; Goldberg L; Ryan T Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP6-7. PubMed ID: 22468875 [No Abstract] [Full Text] [Related]
9. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013. Pauwels K; Huys I; De Nys K; Casteels M; Simoens S Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862 [TBL] [Abstract][Full Text] [Related]
10. Introduction to value-based insurance design. Kelly AM; Cronin P; Carlos RC J Am Coll Radiol; 2008 Nov; 5(11):1118-24. PubMed ID: 18954811 [TBL] [Abstract][Full Text] [Related]
13. Many new cancer drugs in the United Kingdom are facing negative NICE rulings. Low E; J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049 [No Abstract] [Full Text] [Related]
14. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077 [TBL] [Abstract][Full Text] [Related]
15. Applying value-based insurance design to low-value health services. Fendrick AM; Smith DG; Chernew ME Health Aff (Millwood); 2010 Nov; 29(11):2017-21. PubMed ID: 21041741 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief. Chaps NA Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435 [No Abstract] [Full Text] [Related]
17. Keynote comment: reimbursement for molecularly targeted anticancer agents. Tirelli U; de Castro G; Awada A Lancet Oncol; 2006 Jan; 7(1):2-3. PubMed ID: 16389172 [No Abstract] [Full Text] [Related]
18. Applying value-based insurance design to high-cost health services. Robinson JC Health Aff (Millwood); 2010 Nov; 29(11):2009-16. PubMed ID: 21041740 [TBL] [Abstract][Full Text] [Related]
19. Richard Gleave on patients as consumers. Gleave R Health Serv J; 2008 May; ():26. PubMed ID: 18609779 [No Abstract] [Full Text] [Related]
20. Pre-Existing Condition Insurance Plan program. Interim final rule with comment period. Center fors Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS) Fed Regist; 2013 May; 78(99):30218-26. PubMed ID: 23696978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]